Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · IEX Real-Time Price · USD

5.80

-0.26 (-4.29%)

At close: Apr 17, 2024, 4:00 PM

5.93

+0.13 (2.24%)

After-hours: Apr 17, 2024, 4:54 PM EDT

Monte Rosa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	32.04	27.32	15.73	4.01	0.64
Research & Development	111.27	85.06	57.16	24.01	7.35
Operating Expenses	143.31	112.38	72.88	28.01	7.99
Operating Income	-143.31	-112.38	-72.88	-28.01	-7.99
Interest Expense / Income	0	0	0	0	-0
Other Expense / Income	-8.3	-3.88	1.08	7.87	-0.25
Pretax Income	-135.01	-108.5	-73.96	-35.88	-7.74
Income Tax	0.34	0	0	0	0
Net Income	-135.35	-108.5	-73.96	-35.88	-7.74
Shares Outstanding (Basic)	51	47	25	2	5
Shares Outstanding (Diluted)	51	47	25	2	5
Shares Change	8.83%	88.91%	1548.09%	-69.66%	-
EPS (Basic)	-2.63	-2.30	-2.96	-23.65	-1.55
EPS (Diluted)	-2.63	-2.30	-2.96	-23.65	-1.55
Free Cash Flow	-62.78	-105.27	-69.02	-26.44	-7.56
Free Cash Flow Per Share	-1.22	-2.23	-2.76	-17.43	-1.51
EBITDA	-128.79	-99.94	-71.83	-35.34	-7.67
Depreciation & Amortization	6.22	8.56	2.13	0.54	0.07
EBIT	-135.01	-108.5	-73.96	-35.88	-7.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).